Dataset Information

Lutetium ultraphosphate.

ABSTRACT: The structure of the title compound, LuP(5)O(14), comprises puckered eight-membered PO(4) rings linked by the lutetium cations in a complex way, forming a three-dimensional framework. Each eight-membered phosphate ring shares a bridging tetra-hedron with each of four adjacent tetra-hedra, to form layers of PO(4) tetra-hedra. These layers are c/2 in thickness and parallel to the ab plane. Each Lu ion is contained in one such layer, forming bonds to six O atoms in that layer and also to one O atom belonging to a tetra-hedron in each of the layers lying above and below it. The LuO(8) polyhedra are isolated from one another, since they share no common atoms. The Lu ions lie on twofold axes (special position 4e) and the shortest Lu?Lu distance is 5.703?(1)?Å.

SUBMITTER: Horchani-Naifer K

PROVIDER: S-EPMC2961625 | biostudies-literature | 2008 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Lutetium ultraphosphate.

Horchani-Naifer Karima K Férid Mokhtar M

Acta crystallographica. Section E, Structure reports online 20080510 Pt 6

The structure of the title compound, LuP(5)O(14), comprises puckered eight-membered PO(4) rings linked by the lutetium cations in a complex way, forming a three-dimensional framework. Each eight-membered phosphate ring shares a bridging tetra-hedron with each of four adjacent tetra-hedra, to form layers of PO(4) tetra-hedra. These layers are c/2 in thickness and parallel to the ab plane. Each Lu ion is contained in one such layer, forming bonds to six O atoms in that layer and also to one O atom ...[more]

PMID: 21202435

Similar Datasets

Project description:BackgroundMetastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.MethodsWe conducted an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with at least one androgen-receptor-pathway inhibitor and one or two taxane regimens and who had PSMA-positive gallium-68 (68Ga)-labeled PSMA-11 positron-emission tomographic-computed tomographic scans. Patients were randomly assigned in a 2:1 ratio to receive either 177Lu-PSMA-617 (7.4 GBq every 6 weeks for four to six cycles) plus protocol-permitted standard care or standard care alone. Protocol-permitted standard care excluded chemotherapy, immunotherapy, radium-223 (223Ra), and investigational drugs. The alternate primary end points were imaging-based progression-free survival and overall survival, which were powered for hazard ratios of 0.67 and 0.73, respectively. Key secondary end points were objective response, disease control, and time to symptomatic skeletal events. Adverse events during treatment were those occurring no more than 30 days after the last dose and before subsequent anticancer treatment.ResultsFrom June 2018 to mid-October 2019, a total of 831 of 1179 screened patients underwent randomization. The baseline characteristics of the patients were balanced between the groups. The median follow-up was 20.9 months. 177Lu-PSMA-617 plus standard care significantly prolonged, as compared with standard care, both imaging-based progression-free survival (median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57; P<0.001) and overall survival (median, 15.3 vs. 11.3 months; hazard ratio for death, 0.62; 95% CI, 0.52 to 0.74; P<0.001). All the key secondary end points significantly favored 177Lu-PSMA-617. The incidence of adverse events of grade 3 or above was higher with 177Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected.ConclusionsRadioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. (Funded by Endocyte, a Novartis company; VISION ClinicalTrials.gov number, NCT03511664.).

Dataset Information

Lutetium ultraphosphate.

Publications

Lutetium ultraphosphate.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets